Literature DB >> 33209081

Role of Endothelin 1 on Proliferation and Migration of Human MCF-7 Cells.

Irfan Cinar1, Muhammed Yayla1, Muhammet Celik2, Arzu Bilen3, Zafer Bayraktutan2.   

Abstract

OBJECTIVE: The aim of this study was to explore the role of endothelin 1 (ET-1) in human breast cancer proliferation and migration and antagonism of endothelin receptor A (ETAR) and endothelin receptor B (ETBR) by using the non-selective dual ETA/ETB receptor antagonist bosentan and determine its anti-proliferative, anti-metastatic, and apoptotic effects demonstrated by nuclear factor kappa B (NF-kB), vascular endothelial growth factor (VEGF), Caspase 3 and Caspase 9 expression on endothelin-induced proliferation of MCF-7 cell line in vitro.
MATERIALS AND METHODS: A total of 8,000 cells were seeded into e-plates 24 hours after the cells were incubated with or without 10-4 M BOS (1 hour before ET-1 treatment); 10-7, 10-8, and 10-9 M ET-1 for 1-4 days.
RESULTS: Whether ET-1 is present or not in the tumor area, bosentan exerts anti-proliferative effect on breast cancer. However, ET-1 and bosentan group showed important inhibitory effect on tumor migration compared to bosentan alone, which can be attributed to increased activity of ET-1 axis in the presence of ET-1. The imbalance among the NF-kB, caspases, and VEGF, which are predictive factors of carcinogenesis significantly improved after bosentan administration.
CONCLUSION: Our study definitely demonstrated ET-1 and its critical role in cancer progression with apoptotic and anti-apoptotic pathways (NF-κB) and VEGF expression, and migration analyses were also performed. The second major finding was that bosentan inhibited ET-1-mediated effects on tumor proliferation and migration. ©Copyright 2020 by the Atatürk University School of Medicine - Available online at www.eurasianjmed.com.

Entities:  

Keywords:  Bosentan; ET-1; MCF-7; cancer; metastasis

Year:  2020        PMID: 33209081      PMCID: PMC7651758          DOI: 10.5152/eurasianjmed.2020.20033

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  35 in total

Review 1.  Chemopreventive potential of natural compounds in head and neck cancer.

Authors:  Mohammad Aminur Rahman; A R M Ruhul Amin; Dong M Shin
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

2.  ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells.

Authors:  Neil Davie; Stephen J Haleen; Paul D Upton; Julia M Polak; Magdi H Yacoub; Nicholas W Morrell; John Wharton
Journal:  Am J Respir Crit Care Med       Date:  2002-02-01       Impact factor: 21.405

Review 3.  Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy.

Authors:  Wende Kozlow; Theresa A Guise
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-04       Impact factor: 2.673

4.  Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells.

Authors:  M-H Wu; C-Y Huang; J-A Lin; S-W Wang; C-Y Peng; H-C Cheng; C-H Tang
Journal:  Oncogene       Date:  2013-04-15       Impact factor: 9.867

5.  Endothelin-1-induced mitogenic responses of Chinese hamster ovary cells expressing human endothelinA: the role of a wortmannin-sensitive signaling pathway.

Authors:  F Sugawara; H Ninomiya; Y Okamoto; S Miwa; O Mazda; Y Katsura; T Masaki
Journal:  Mol Pharmacol       Date:  1996-03       Impact factor: 4.436

6.  Andrographolide inhibits hypoxia-induced hypoxia-inducible factor 1α and endothelin 1 expression through the heme oxygenase 1/CO/cGMP/MKP-5 pathways in EA.hy926 cells.

Authors:  Hung-Chih Lin; Shih-Li Su; Wan-Chun Lin; Ai-Hsuan Lin; Ya-Chen Yang; Chong-Kuei Lii; Haw-Wen Chen
Journal:  Environ Toxicol       Date:  2017-11-22       Impact factor: 4.119

Review 7.  Role of endothelin-1 in osteoblastic bone metastases.

Authors:  Theresa A Guise; Juan Juan Yin; Khalid S Mohammad
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

8.  Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion.

Authors:  M Smollich; M Götte; C Kersting; J Fischgräbe; L Kiesel; P Wülfing
Journal:  Breast Cancer Res Treat       Date:  2007-04-28       Impact factor: 4.872

9.  Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats.

Authors:  N V Rajeshkumar; Aarati Rai; Anil Gulati
Journal:  Breast Cancer Res Treat       Date:  2005-12       Impact factor: 4.872

10.  Endothelin receptors as novel targets in tumor therapy.

Authors:  Anna Bagnato; Pier Giorgio Natali
Journal:  J Transl Med       Date:  2004-05-27       Impact factor: 5.531

View more
  1 in total

1.  Transcriptome study of oleanolic acid in the inhibition of breast tumor growth based on high-throughput sequencing.

Authors:  Zhuoran Liang; Ruolan Pan; Xia Meng; Jinxing Su; Yong Guo; Gang Wei; Zhi Zhang; Kan He
Journal:  Aging (Albany NY)       Date:  2021-10-04       Impact factor: 5.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.